Therapeutic Advances in Cutaneous T-Cell Lymphoma (CTCL): From Retinoids to Rexinoids
- 1 February 2006
- journal article
- review article
- Published by Elsevier in Seminars in Oncology
- Vol. 33, 7-10
- https://doi.org/10.1053/j.seminoncol.2005.12.016
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Comparison of selective retinoic acid receptor– and retinoic X receptor–mediated efficacy, tolerance, and survival in cutaneous t-cell lymphomaJournal of the American Academy of Dermatology, 2004
- Combination of Bexarotene and Psoralen-UVA Therapy in a Patient with Mycosis fungoidesDermatology, 2004
- Bexarotene: a clinical reviewExpert Review of Anticancer Therapy, 2004
- Low-dose oral bexarotene in combination with low-dose interferon alfa in the treatment of cutaneous T-cell lymphoma: clinical synergism and possible immunologic mechanismsJournal of the American Academy of Dermatology, 2004
- Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trialJournal of the American Academy of Dermatology, 2003
- Mycosis fungoides shows concurrent deregulation of multiple genes involved in the TNF signaling pathway: an expression profile studyBlood, 2003
- Phase 1 and 2 Trial of Bexarotene Gel for Skin-Directed Treatment of Patients With Cutaneous T-Cell LymphomaArchives of Dermatology, 2002
- Bexarotene Is Effective and Safe for Treatment of Refractory Advanced-Stage Cutaneous T-Cell Lymphoma: Multinational Phase II-III Trial ResultsJournal of Clinical Oncology, 2001
- The retinoid signaling pathway: molecular and genetic analysesSeminars in Cell Biology, 1994
- Retinoids in Cutaneous T Cell LymphomasDermatology, 1987